Traws Pharma completes ratutrelvir Phase 2 enrollment; tivoxavir influenza prophylaxis study set for June 2026

Traws Pharma, Inc.

Ratutrelvir study fully enrolled (90 pts); shows fewer AEs, no viral rebound, faster symptom resolution vs PAXLOVID.
Separate arm for PAXLOVID-ineligible patients addresses high-risk group with few effective options.
Tivoxavir marboxil compressed tablet predicted to offer 28-day influenza protection; challenge study secured for June 2026 at hVIVO.
Ratutrelvir's profile may support future studies in reducing risk of Long COVID via early viral clearance.
CEO states advancement of antiviral portfolio provides significant value inflection points.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.